Meeting
2016 ASCO Annual Meeting
Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
Authors
Robert W. Chen
City of Hope National Medical Center, Duarte, CA
Robert W. Chen , Pier Luigi Zinzani , Michelle A. Fanale , Philippe Armand , Nathalie Johnson , Vincent Ribrag , John A. Radford , Akihiro Tomita , Margaret Ann Shipp , Yang Wang , Alejandro Daniel Ricart , Arun Balakumaran , Craig H. Moskowitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02453594
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7555)
DOI
10.1200/JCO.2016.34.15_suppl.7555
Abstract #
7555
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
First Author: Philippe Armand
Poster
2021 ASCO Annual Meeting
A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
First Author: Nikhil Shukla
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya
Poster
2015 ASCO Annual Meeting
KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.
First Author: Dean F. Bajorin